Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03003962 · ClinicalTrials.gov registry record · Phase 3

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

A Phase 3 study of Non-Small-Cell Lung Carcinoma NSCLC, sponsored by AstraZeneca.

Active
Registry status
Phase 3
Development phase
669
Enrollment target
20
Study locations

NCT03003962: Active Phase 3 study of Non-Small-Cell Lung Carcinoma NSCLC, sponsored by AstraZeneca.

NCT03003962 is a Phase 3 study of Non-Small-Cell Lung Carcinoma NSCLC that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 669 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (13% lower). The trial reports 20 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03003962, a Phase 3 study of Non-Small-Cell Lung Carcinoma NSCLC, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
669 participants
Enrollment target
20
Study locations

Study Summary

This is a randomized, open-label, multi-center Phase III study to determine the efficacy and safety of durvalumab versus platinum-based SoC chemotherapy in the first-line treatment of advanced NSCLC in patients who are epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type and with PD-L1 high expression (PEARL)

Primary Outcome

OS is defined as the time from the date of randomization until death due to any cause (date of death or censoring-date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive.

Conditions Studied

Non-Small-Cell Lung Carcinoma NSCLC

Interventions

  • DRUG Gemcitabine + cisplatin
  • DRUG Gemcitabine + carboplatin
  • DRUG Durvalumab (MEDI4736)
  • DRUG Paclitaxel + carboplatin
  • DRUG Pemetrexed + cisplatin

Study Locations (20)

Other

  • Research Site - Box Hill
  • Research Site - Gosford
  • Research Site - Kogarah
  • Research Site - St Leonards
  • Research Site - Beijing
  • Research Site - Beijing
  • Research Site - Beijing
  • Research Site - Bengbu
  • Research Site - Changchun
  • Research Site - Changsha
  • Research Site - Chengdu
  • Research Site - Chongqing
  • Research Site - Guangzhou
  • Research Site - Guangzhou
  • Research Site - Haikou
  • Research Site - Hangzhou
  • Research Site - Hangzhou
  • Research Site - Hangzhou
  • Research Site - Hangzhou

California

  • Research Site - Anaheim

Trial Details

FieldValue
Enrollment Target 669 participants
Start Date 2017-01-02
Est. Completion 2026-06-30
Phase Phase 3
AstraZeneca

1,285 total trials

What the registry record for NCT03003962 still lists

NCT03003962 is an interventional study that assigns participants to a tested intervention. The registered 669 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (13% lower).

The record links to 1 condition, with Non-Small-Cell Lung Carcinoma NSCLC appearing as the primary indexed condition, and to 5 interventions - of which Gemcitabine + cisplatin is the first listed.

NCT03003962 names 20 study sites across 2 states, led by Other, California.

Frequently Asked Questions

What is clinical trial NCT03003962 about?

NCT03003962 is a clinical study titled "Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)". This is a randomized, open-label, multi-center Phase III study to determine the efficacy and safety of durvalumab versus platinum-based SoC chemotherapy in the first-line treatment of advanced NSCLC in patients who are epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild...

What is the current status of trial NCT03003962?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 669 participants. The study started on 2017-01-02. Estimated completion is 2026-06-30.

What conditions does trial NCT03003962 study?

This clinical trial studies the following conditions: Non-Small-Cell Lung Carcinoma NSCLC.

What interventions are being tested in trial NCT03003962?

The interventions under investigation include: Gemcitabine + cisplatin (DRUG), Gemcitabine + carboplatin (DRUG), Durvalumab (MEDI4736) (DRUG), Paclitaxel + carboplatin (DRUG), Pemetrexed + cisplatin (DRUG).

Who is sponsoring clinical trial NCT03003962?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03003962 being conducted?

This trial has 20 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small-Cell Lung Carcinoma NSCLC

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03003962's enrollment target sits among peer trials

669 547th of 2000 higher than 1,453 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02984761 · 670 participants · NA

    Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy

  • NCT05727904 · 670 participants · Phase 3

    Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

  • NCT06223867 · 670 participants · NA

    Efficacy, Effectiveness, and Implementation of Jaspr Health in Emergency Department- Part A

  • NCT04155034 · 668 participants · Phase 3

    S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03003962, the US trial registry maintained by the National Library of Medicine. NCT03003962 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.